Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aderbasib - Incyte Corporation

Next Previous
X
Search
Drug Profile

Aderbasib - Incyte Corporation

Alternative Names: INC B007839; INCB 7839

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Class Amines; Antineoplastics; Aza compounds; Carboxylic acids; Cyclopropanes; Esters; Piperazines; Piperidines; Small molecules; Spiro compounds
  • Mechanism of Action ADAM10 protein inhibitors; Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HER2 positive breast cancer

Most Recent Events

  • 07 Jun 2010 Efficacy and adverse events data from a phase I/II trial in HER2-positive-breast-cancer presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
  • 13 Dec 2009 Efficacy, adverse events, pharmacocynamics and pharmacokinetics data from a phase I/II trial in HER2-positive-breast-cancer presented at the 32nd San Antonio Breast Cancer Symposium (SABCS-2009) ,
  • 26 Feb 2008 Phase-II clinical trials in HER2-positive-breast-cancer (monotherapy) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top